Rinatabart sesutecan is an antibody-drug conjugate that binds folate receptor alpha on tumor cells and, after uptake and linker cleavage, releases the topoisomerase I inhibitor exatecan. It is being studied in platinum-sensitive ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
GEN-1184, PRO-1184, Rina-S
Drug type
Antibody-drug conjugate
Targets
folate receptor alpha (FOLR1), topoisomerase I (TOP1) (secondary target)
Mechanism
Cytotoxic, directed at folate receptor alpha (FOLR1)
Pathways
DNA replication inhibition, DNA damage response, apoptosis
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.